Shares of Compugen Ltd. (NASDAQ:CGEN) were up 3.9% during mid-day trading on Monday . The company traded as high as $6.94 and last traded at $6.91, with a volume of 167,514 shares changing hands. The stock had previously closed at $6.65.

A number of analysts have recently issued reports on CGEN shares. FBR & Co reiterated a “buy” rating on shares of Compugen in a research report on Wednesday, June 22nd. Zacks Investment Research downgraded Compugen from a “hold” rating to a “sell” rating in a research report on Tuesday, July 12th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $10.79.

The stock’s market cap is $349.83 million. The firm’s 50-day moving average price is $6.62 and its 200 day moving average price is $6.07.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.